CSF biomarkers support AD diagnosis in nearly 90% of clinical cases

SAN DIEGO — Cerebrospinal fluid biomarkers supported the clinical diagnosis of Alzheimer’s disease in a small cohort of patients, per a poster presentation at the Alzheimer’s Association International Conference.
“We analyzed the use of biomarkers in our clinical setting ... [to check] the accuracy in which these biomarkers serve as a diagnostic tool in the clinical setting of a normal patient with suspected Alzheimer’s disease,” Pablo Agüero, MD, of Jiménez Díaz Foundation University Hospital in Madrid, said.
Agüero and colleagues

SAN DIEGO — Cerebrospinal fluid biomarkers supported the clinical diagnosis of Alzheimer’s disease in a small cohort of patients, per a poster presentation at the Alzheimer’s Association International Conference.
“We analyzed the use of biomarkers in our clinical setting … [to check] the accuracy in which these biomarkers serve as a diagnostic tool in the clinical setting of a normal patient with suspected Alzheimer’s disease,” Pablo Agüero, MD, of Jiménez Díaz Foundation University Hospital in Madrid, said.
Agüero and colleagues